Physician profile
Peter Y Chang
NPI 1801107859
$992,200.56
in general payments reported to CMS, 2019-2025
47 companies · $201K in 2025
The $201K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $29K · 2021: $149K · 2022: $227K · 2023: $165K · 2024: $204K · 2025: $201K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $402K · Honoraria: $49K · Consulting Fee: $46K · Travel and Lodging: $31K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Food and Beverage: $21K · Education: $93.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $402,211.61 |
| Honoraria | $48,567.50 |
| Consulting Fee | $45,920.00 |
| Travel and Lodging | $31,498.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,484.38 |
| Food and Beverage | $20,737.84 |
| Education | $93.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $609,689.67 | 2020-2025 | Acthar |
| Eyepoint US, INC. | $134,034.64 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $66,262.05 | 2022-2025 | Xipere, Xiidra, Miebo |
| Regeneron Healthcare Solutions, INC. | $52,716.76 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $45,086.09 | 2019-2024 | Iluvien, Yutiq |
| Ani Pharmaceuticals, INC. | $20,310.23 | 2023-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Alcon Vision LLC | $14,682.75 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Astellas Pharma US INC | $13,481.18 | 2023-2025 | Izervay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,175.97 | 2022-2023 | |
| Abbvie INC. | $7,900.52 | 2020-2025 | Durysta, Ozurdex, Vuity |
| X4 Pharmaceuticals, INC. | $6,000.00 | 2025 | Xolremdi |
| Genentech USA, INC. | $3,276.94 | 2022-2025 | Vabysmo, Susvimo |
| Dutch Ophthalmic, USA | $1,842.11 | 2022-2024 | Eva, Combined Machine, Tissueblue |
| Genentech, INC. | $1,680.00 | 2025 | Vabysmo, Susvimo |
| Sun Pharmaceutical Industries INC. | $637.31 | 2019-2025 | Cequa |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $634.76 | 2019-2022 | |
| Dompe US, INC. | $566.62 | 2020-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $485.77 | 2019-2021 | |
| Samsara Vision | $414.73 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Tarsus Pharmaceuticals, INC. | $375.40 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $359.66 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Beaver-Visitec International, INC. | $350.00 | 2022 | |
| Aerie Pharmaceuticals, INC. | $330.15 | 2019-2021 | |
| Ocular Therapeutix, INC. | $324.30 | 2020-2025 | Dextenza |
| Sight Sciences, INC. | $302.07 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $290.25 | 2019 | |
| Kala Pharmaceuticals, INC. | $267.58 | 2019-2021 | |
| Oculus Surgical INC. | $206.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $199.14 | 2019-2022 | |
| Harrow Eye, LLC | $198.68 | 2024 | Iheezo, Vevye |
| Biogen, INC. | $150.00 | 2022 | |
| Amgen INC. | $129.20 | 2024-2025 | Tepezza, Uplizna, Tavneos |
| Horizon Therapeutics Plc | $113.89 | 2021-2023 | Tepezza |
| New World Medical,INC. | $111.94 | 2022 | |
| Astellas Pharma Global Development | $109.22 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $104.86 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $87.34 | 2022 | |
| Rayner Intraocular Lenses Limited | $66.48 | 2022-2025 | Omidria, Rayone Emv, Rayone Spheric |
| Biotissue Holdings INC. | $53.13 | 2019-2025 | |
| Apellis Pharmaceuticals, INC. | $40.26 | 2023-2024 | Syfovre |
| Coherus Oncology, INC. | $37.59 | 2022 | |
| Thea Pharma INC. | $36.03 | 2024-2025 | Iyuzeh |
| Neurotech Pharmaceuticals, INC. | $24.17 | 2025 | |
| Shire North American Group INC | $23.82 | 2019 | |
| Glaukos Corporation | $17.84 | 2019 | |
| Ivantis, INC | $13.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.